Conservative treatment for the management

Appendix 2
Author Yea
r
PUBMedId Data patients Intervention Comparator outcome Included/
Excluded
Alaraj, A.,
Wallace, A.,
Tesoro, E.,
Ruland, S.,
Amin-Hanjani,
S., Charbel, F.
T., &Aletich, V.
2010 21990651
With augmented
exposure to heparin
during
neurointerventional
procedures, HIT
incidence would
carry on to amplify.
Patients developing
HIT-II are at greater
risk of suffering
from adverse
thromboembolic
complications.
neurological
patients
heparin Argatroban,
warfarin,
lepirudin.
Bivalirudin,
Danaparoid
heparin induced
thrombocytopeni
a (HIT)
Excuded- No
comparison with
enoxaparin

Antman, E. M.,
Morrow, D. A.,
McCabe, C. H.,
Murphy, S. A.,
Ruda, M.,
Sadowski, Z., ...
& White, H. D.
(2006).
2006 16537665 Myocardial
infarction
management with
enoxaparin during
index hospitalization
is better to
management with
unfractionated
heparin for
approximately 48
hours, however is
connected with an
augmentation in
significant bleeding
episodes.
ST-elevation
myocardial
infarction
heparin enoxaparin nonfatal recurrent
myocardial
infarction or
death
Exc- No DVT
Armstrong, P. 2006 16682709 Enoxaparin had ASSENT-3 and heparin enoxaparin Reinfarction, Exc- No DVT

W., Chang, W.
C., Wallentin,
L., Goldstein,
P., Granger, C.
B., Bogaerts,
K., ... & Van de
Werf, F.
greater benefits
amongst urgently
revascularized
patients, but was
associated to excess
of ICH during the
ASSENT-3 PLUS
trial, particularly
amid females
ASSENT-3 PLUS
patients
mortality, or
refractory
ischemia
Brieger, D.,
Collet, J. P.,
Silvain, J.,
Landivier, A.,
Barthélémy, O.,
Beygui, F., ...
&Costagliola,
2001 20578166 Enoxaparin was
responsible for a
decrease in every one
of ischemic
complications,
additionally
recurrent therapeutic
Primary PCI
(pPCI) patients for
ST elevation
heparin enoxaparin Safety and
efficacy
endpoints
Exc- No DVT

D. anticoagulation, and
failed to induce any
major bleeding
event, in contrast to
unfractionated
heparin. Patients
who had been
administered
enoxaparin
demonstrated an
increased likelihood
of being
therapeutically
anticoagulated for
the duration of the
process (68% vs.

50%, P < 0.0001)
and also
demonstrated a
decreased
susceptibility to
suffer from recurrent
myocardial
infarction (MI) while
being admitted to the
hospital or death
(adjusted OR 0.28
95% CI (0.12–0.68)
or by 30 days
(adjusted OR 0.35
95% CI 0.16–0.81).
A decrease was also

observed in all cause
mortality in hospital
(adjusted OR 0.32,
95% CI (0.12–0.85)
and to 30 days
(adjusted OR 0.40
95% CI 0.17–0.99).
Bugiardini, R.,
Dorobantu, M.,
Vasiljevic, Z.,
Kedev, S.,
Knežević, B.,
Miličić, D., ...
& Ricci, B.
2015
25988359
Combination of UFH
and Clopidogrel was
allied with a
significant mortality
decrease amongst
STEMI patients who
did not undergo
reperfusion therapy,
and failed to
Patients from
International
Survey on Acute
Coronary
Syndromes in
Transition
Countries
unfractionated
heparin
enoxaparin in-hospital
mortality,
clinically
significant
bleeding, and
intracranial
hemorrhages
Exc-No
comparison with
enoxaparin

considerably
augment the danger
of major bleeding.
Çaça, I., Şahin,
A., Cingü, A.
K., Ari, Ş.,
Alakuş, F.,
&Çinar, Y.
2012 23166871 Cataract
surgery complication
s connected with
postoperative
inflammatory
response appeared to
reduce with
administration of
enoxaparin in
intraocular infusion
solution.
53 children having
congenital cataract
enoxaparin none inflammatory
response
Exc- congenita
cataract surgery
and no comparison
Dee, B.,
Thomas, L. L.,
2014 24733133 A 63-year-old male
suffering from renal
63-year-old
Caucasian male
Argatroban
and alteplase
none HITT Exc- No
comparison o

& Gulbis, A. amyloidosis, in
addition to superior
vena cava syndrome
(SVC) secondary to
heparin-induced
thrombocytopenia
with thrombosis
(HITT) underwent
successful treatment
with argatroban
administration and
CDT with alteplase
administration.
heparin with
enoxaparin
El-Rayes, M.,
Schampaert, E.,
Tardif, J. C.,
2010 20931096 No substantial
variation among
unfractionated
STEMI patients
obtaining
fibrinolytic therapy
unfractionated
heparin
enoxaparin safety and
efficacy
Exc- Acute
Myocardial
Infarction, no DVT

Eisenberg, M.
J., Afilalo, M.,
Kouz, S., ...
&Dery, J. P.
heparin and
enoxaparin group in
safety and
effectiveness
Gabriel, R. S.,
& White, H. D.
2007 17867915 The overall clinical
advantage of
enoxaparin greater
than unfractionated
heparin was
maintained not
considering if all
patients had been
administered
clopidogrel, or if
percutaneous
coronary
Patients from
ExTRACT-TIMI 2
5 trial
Unfractionated
heparin
enoxaparin nonfatal
myocardial
infarction, major
bleeding or death
Exc- Myocardia
infarction, no DVT

intervention had
been conducted.
Hardy, R. G.,
Williams, L., &
Dixon, J. M.
2008 18425795 LMWH
thromboprophylaxis
demonstrated a
significant
association with an
augmentation in
haemorrhagic
complications
following breast
surgery, in
comparison to UFH.
Patients with
postoperative
breast haematoma
unfractionated
heparin
enoxaparin Haematoma
rates, surgical
intervention
Exc- breast surgery
Heyes, G. J.,
Tucker, A.,
Michael, A. L.
2015 26037973 Conservative
treatment for the
management of
945 consecutive
patients
none none incidence of
DVT, incidence
of pulmonary
Exc- DVT
incidence, no
comparison

R., & Wallace,
R. G. H.
Tendo Achilles was
associated with a
significant increase
in the occurrence of
symptomatic DVT in
the general
population
embolism
Ikesaka, R.,
Delluc, A., Le
Gal, G., &
Carrier, M.
2014 24508449 Adjustment in the
dosage of heparin for
thromboprophylaxis
after bariatric
surgery
demonstrated a
correlation with
decreased hospital
VTE rate, in contrast
6 studies Heparin
prophylaxis
none hospital rate of
VTE and major
bleeding
Exc- No
comparison with
enoxaparin

to not adjusting
heparin dosage, even
though there was no
statistical
significance.
Joannidis, M.,
Kountchev, J.,
Rauchenzauner,
M.,
Schusterschitz,
N., Ulmer, H.,
Mayr, A.,
&Bellmann, R.
2007 17563874 Enoxaparin can be
carefully
administered for
anticoagulation at the
time of CVVH
causing greater filter
lifespan, in contrast
to unfractionated
heparin.
40 adult surgical
ICU and medical
patients
unfractionated
heparin
enoxaparin filter life span,
major bleeding,
cost analysis
Exc- continuous
veno-venous
hemofiltration, no
DVT
Jones, H. U.,
Muhlestein, J.
2005 16039196 Early postoperative
administration of
2,977 successive
valve or open-
unfractionated
heparin
enoxaparin surgical re-
exploration and
Exc-No DVT

B., Jones, K.
W., Renlund, D.
G., Bair, T. L.,
Bunch, T. J., ...
& Doty, D. B.
unfractionated
heparin and
enoxaparin is allied
with a considerable
augmentation in
postoperative
bleeding re-
exploration, at a
considerably delayed
time, following the
initial surgery.
heart surgery
patients
time till follow-
up
Kim, G. H.,
Hahn, D. K.,
Kellner, C. P.,
Komotar, R. J.,
Starke, R.,
2009 18976056 aSAH patients who
were administered
heparin do not show
any relatively higher
risk of HIT II
300 aSAH
patients receving
thromboprophylaxi
s
heparin enoxaparin HIT II incidence Exc-heparin-
induced
thrombocytopenia
incidence, no DVT

Garrett, M.
C., ... &
Connolly, E. S.
development,
compared to patients
who were
administered
enoxaparin.
Kim, S. H.,
Patel, N.,
Thapar, K.,
Pandurangadu,
A. V., &Bahl,
A.
2018 29928127 Isolated proximal
GSV thrombosis,
though no extremely
frequent, most
commonly leads to
the onset or progress
of PE or DVT
21,716 patients none none Advancement of
GSV thrombosis
to PE and DVT
Exc- No
comparison o
heparin with
enoxaparin
Kothari, S. N.,
Lambert, P. J.,
&Mathiason,
M. A.
2007 18005758 There was
0 incidence of
DVT in both cohorts.
While one patient
Laparoscopic
gastric bypass
patients
Heparin Enoxaparin DVT and post-
operative
transfusion
Exc- sincethe
patients had been
subjected to
laparoscopic

subjected to heparin
injection
demonstrated signs
of pulmonary
embolism, 14
patients who
administered
enoxaparin
necessitated post-
operative
transfusions, in
comparison to 3who
are injected heparin.
Additionally,
patients with
enoxaparin injection
gastric bypass

also needed bleeding
re-exploration.
Letertre, L. R.,
Gudmundsdottir
, B. R., Francis,
C. W., Gosselin,
R. C.,
Skeppholm, M.,
Malmstrom, R.
E., ...
&Onundarson,
P. T.
2016 26924677 The dFiix‐PT that
utilises TP single
dilution can be used
for assessing the
impact of
anticoagulants.
None anticoagulants none assay Exc- No DVT
Leykum, L.,
Pugh, J.,
Diuguid, D., &
Papadopoulos,
2006 17219491 Administration of
enoxaparin was
associated with a
reduction in cost, by
Medical patients
who were
considered
appropriate for
Heparin Enoxoparin Costs and QALY Exc- since the
researchers did no
determine the
impactof

K. as much as $28.61,
in contrast to
heparinthat resulted
in saving 0.00629
QALYs, which
corresponded
to $4550.17/QALY.
Consistency was
observed in the
increased
effectiveness and
decreased
cost. Injection of
heparin was found to
be less expensive,
however, it was
VTE prophylaxis enoxaparin and
heparin on
recurrence o
rhombus

completely reliant on
price of the
medication, bed
utilisation in
thehealthcare
facility, and the
length of
hospitalization
required for the
patients.
Li, W., Wang,
P., Le, S., Xi,
W., Wang, J.,
Yin, L., ... &
Wang, Z.
2019 32030244
Early prophylactic
LMWH
anticoagulation
could not decrease
embolism incidence
after MICS
473 MICS patients LMWH
anticoagulatio
n
No LMWH Embolism
incidence, major
bleeding,
erythrocyte
transfusion,
drainage volume
Exc- No DVT, No
comparison with
enoxaparin

and duration
Minshall, C. T.,
Eriksson, E. A.,
Leon, S. M.,
Doben, A. R.,
McKinzie, B.
P., &Fakhry, S.
M.
2011 21825943 LMWH is an
effective CP method
amid TBI patients
and has a decreased
hemorrhagic and
venous
thromboembolic
complication rate, in
comparison to UFH.
TBI patients low-
molecular-
weight heparin
unfractionate
d heparin
intracranial
hemorrhagic
complication,
DVT,
pulmonary
embolus
Exc- No
comparison with
enoxaparin
Montalescot,
G., Gallo, R.,
White, H. D.,
Cohen, M.,
Steg, P. G.,
Aylward, P.
2009 19926048 Low 1-year mortality
rates were observed
and these were
equivalent amongst
patients receiving
UFH and enoxaparin
STEEPLE patients unfractionated
heparin
enoxaparin All-cause
mortality
Exc- No DVT
percutaneous
coronary
intervention

E., ... &Desmet,
W. J.
at the time of
elective PCI.
Riess, H.,
Pelzer, U.,
Deutschinoff,
G., Opitz, B.,
Stauch, M.,
Reitzig, P., ...
&Oettle, H.
2009 Enoxaparin is safe
and efficacious for
the primary sVTE
prevention, when
administered in
combination with
cytotoxic
chemotherapy
amongst APC
patients
APC patients enoxaparin chemotherap
y
Tumor-
associated fatal
hemorrhage,
major bleeding
Exc- No DVT
pancreatic cancer
Rutherford, E.
J., Schooler, W.
G., Sredzienski,
E., Abrams, J.
2005 15995464 enoxaparin is not
suitable for patients
who are critically ill.
Patients who suffer
17 patients who
were critically ill
enoxaparin none Anti-Xa activity
and adverse
events
Exc- No DVT

E., &Skeete, D.
A.
from renal
insufficiency were
found to require an
augmented interval
of daily dosing or
administration of
enoxaparin. Anti-Xa
levels did not show
any significant
correlation with the
risk of suffering
from
thromboembolic
complications.
Senaran, H.,
Acaroğlu, E.,
2006 16333632 DVT was found to
develop amongst the
100 patients Heparin Enoxaparin Safety and
efficacy
Exc- since the
patients had been

Özdemir, H. M.,
& Atilla, B.
patients who had
been injected heparin
at the end of their
hospitalization. Late
DVT developed in 2
patients who were
administered
enoxaparin, during
post operation
periods. Minor and
major bleeding was
observed in 7
patients in both the
groups. Those who
were administered
heparin werefound to
subjected to
hipreplacement
surgery

discontinue the
medication due to
renal dysfunction,
hepatic
dysfunction,and
serious wound
discharge.
Silvain, J.,
Beygui, F.,
Barthélémy, O.,
Pollack, C.,
Cohen, M.,
Zeymer, U., ...
&Vicaut, E.
2012 22306479 Enoxaparin appeared
more effective than
unfractionated
heparin in decreasing
bleeding outcomes
and mortality at the
time of percutaneous
coronary
intervention and
23 trials unfractionated
heparin
enoxaparin Mortality and
major bleeding
Exc- No DVT
percutaneous
coronary
intervention,
secondary research

predominantly
amongst patients
subjected primary
percutaneous
coronary
intervention, in
relation to ST
elevation myocardial
infarction.
Welsh, R. C.,
Gordon, P.,
Westerhout, C.
M., Buller, C.
E., O'Neill, B.,
& Armstrong,
P. W.
2007 17295333 Single SQ dosage of
enoxaparin failed to
demonstrate
significant anti‐Xa
levels ≥0.5 U/ml
amongst the STEMI
patients. When
STEMI patients intravenous
(IV)
enoxaparin
None anti‐Xa level Exc- No
comparison with
heparin,
percutaneous
coronary
intervention

administered in
combination with
supplemental IV
enoxaparin, the
researchers obtained
sufficient anti‐Xa
levels amongst all
patients with a small
number of patients
demonstrating levels
>1.5 U/ml.
Chong, B. H.,
Brighton, T. A.,
Baker, R. I.,
Thurlow, P.,
Lee, C. H., &
2005 16082604 Patients treated with
enoxaparin
demonstrated an
inclination towards
decreased relapse
298 with
symptomatic DVT
Unfractionated
heparin
Once daily
enoxaparin
Recurrent DVT,
bleeding events
and pulmonary
emboli
Included

ASTH DVT
Study Group
of pulmonary
embolism(1.3% vs.
4.1%; p = 0.17) and
DVT (1.3% vs.
5.4%; p = 0.060), in
comparison to those
who had been
injected
unfractionated
heparin. Incidence
ofadverse events and
bleeding events in
both the groups were
similar.
Schobess, R., 2006 17145610 No significant 80 children aged Heparin Enoxaparin Long-term Included

During, C.,
Bidlingmaier,
C., Heinecke,
A., Merkel, N.,
& Nowak-Gottl,
U.
difference was
observed between
enoxaparin and
heparin
administration. No
instances of therapy-
related death or
bleeding. 6.3%
children showed
symptoms of
postthrombotic
syndrome and
relapse of DVT was
noted in two cases in
each group. Those
being injected with
over 3 months with
DVT
efficacy and
safety

enoxaparin reported
minor bleeding. One
patient suffered from
ankle joint bleeding,
and another with
cerebral venous sinus
thrombosis reported
signs of minor
subdural bleeding.
Arnold, J. D.,
Dart, B. W.,
Barker, D. E.,
Maxwell, R. A.,
Burkholder, H.
C., Mejia, V.
A., & Smith, P.
2001 20583509 6.75% patients who
had been
administered
enoxaparin
demonstrated signs
of proximal lower
text DVT, in
476 adult trauma
patients with 237
given enoxaparin
and 239
administered
heparin
Heparin Enoxaparin Complications
and expense of
standard dose
enoxaparin, in
comparison
to three times
subcutaneous
Included

W. comparison to 7.11%
patients injected with
heparin. Risk factors
among these patients
for DVT included
closed head injury
and spinal cord
injury.
However, no
difference was
identified between
incidences of
bleedingand
pulmonary emboli,
between the patient
groups.
administration of
unfractionated
heparin

Argenta, C.,
Ferreira, M. A.
P., Sander, G.
B., & Moreira,
L. B.
2018 21839908 There were no
statistically
significant variations
between the groups
receiving heparin
and enoxaparin, in
relation to blood
transfusion, number
of bleeding events,
bleeding, recurrent
VTE or death. While
the daily mean cost
for enoxaparin per
patient was found
tobe US$9.87 ±
167 patients, aged
18-92 years.
Heparin Enoxaparin Activated partial
thromboplastin
time, blood
transfusion,
bleeding, death
and recurrent
VTE
Included

$2.44, it was
US$12.63 ± $4.01
for unfractionated
heparin
injection. The total
cost was found to be
US$69.11 and
US$88.39 for
enoxaparin and
heparin,
respectively.
Sherman, D. G.,
Albers, G. W.,
Bladin, C.,
Fieschi, C.,
Gabbai, A. A.,
2007 17448820 The risk of suffering
from
thromboembolism
decreased upon
administration of
1762 patients
suffering from
acute ischemic
stroke
Heparin Enoxaparin Asymptomatic or
symptomatic
DVT, fatal
pulmonary
embolism,
Included

Kase, C. S., ...
& PREVAIL
Investigators.
enoxaparin by as
much as 43%, in
comparison to
injection of
unfractionated
heparin (68 [10%] vs
121 [18%]; relative
risk 0·57, 95% CI
0·44–0·76,
p=0·0001; difference
−7·9%,−11·6 to
−4·2). No
statistically
significant
differences were
observed in
symptomatic
pulmonary
embolism, major
extracranial
haemorrhage,
symptomatic
intracranial
haemorrhage,
andall-cause
mortality.

accordance to
bleeding events
amongst the patients
with unfractionated
heparin (71 [8%];
p=0·83) or
enoxaparin (69
[8%]). No
differences were also
observed in relation
to symptomatic
intracranial
haemorrhage (4 [1%]
vs 6
[1%],respectively;
p=0·55). However,

extracranial bleeding
rate was greater
among patients who
were injected
enoxaparin, in
contrast to
unfractionated
heparin (7 [1%] vs 0;
p=0·015).
Olson, E. J.,
Bandle, J.,
Calvo, R. Y.,
Shackford, S.
R., Dunne, C.
E., Van Gent, J.
M., ... &Sise, C.
2015 26317819 Unfractionated
heparin
administration was
found to be non-
inferior, in contrast
to enoxaparin
administration
495 trauma patients Heparin Enoxaparin Venous
thromboembolis
m prophylaxis,
following a
trauma
Included

B. (absolute VTE risk
difference, 3.1%;
95% confidence
interval, −1.6% to
7.7%; p = 0.196);
there was no major
differencebetween
the two treatment
groups, in relation to
the onset of adverse
events. While
screening the
ultrasound group,
unfractionated
heparin non-
inferiority was not

conclusive (absolute
VTE risk difference,
6.5%; 95%
confidence interval,
−2.9% to 15.8%; p =
0.179).
Pharmaceutical
expenditure for
injection
ofunfractionated
heparin ($2,809) was
20-fold lesser than
that of enoxaparin
($54,138).